1-5 of 5
Keqin Qi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Binod Dhakal, Hermann Einsele, Jordan M Schecter, Tito Roccia, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Kaitlyn Connors, Keqin Qi, Anil Londhe, Robin Carson, Jennifer Voelker, Patricia Cost, Satish Valluri, Erika Florendo, Lida Pacaud, Kwee Yong
Journal: Blood
Blood (2022) 140 (Supplement 1): 4320–4322.
https://doi.org/10.1182/blood-2022-159151
Published: 2022
Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianaya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 228–230.
https://doi.org/10.1182/blood-2022-156070
Published: 2022
Journal Articles

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Simon Rule, Martin H. Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MRCP, FRPath, PhD, Brad S. Kahl, MD, Jose Angel Hernandez-Rivas, MD PhD, Keqin Qi, PhD, Sanjay Deshpande, Lori Parisi, Michael L. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1538.
https://doi.org/10.1182/blood-2019-124691
Published: 2019
Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 863.
https://doi.org/10.1182/blood-2019-122497
Published: 2019
Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 152.
https://doi.org/10.1182/blood-2018-152
Published: 2018